All News

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.

In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.

Current cigarette and electronic nicotine delivery systems (ENDS) were associated with elevated wheezing, but not ENDS use alone, according to a new study.

Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).

These factors could provide a scientific basis for consistency evaluations of the quality and efficacy of insulin biosimilars, study authors wrote.

Democrats look to build on the Inflation Reduction Act, and both parties seem to want to reform the pharmacy benefit manager industry; the US federal government and Gilead Sciences will go to trial this week in a multibillion-dollar dispute; the US Surgeon General warns that loneliness is a public health threat.

Panelists at the 2023 Asembia Specialty Pharmacy Summit discussed the myriad of ways that the drug pricing policies of the Inflation Reduction Act (IRA), such as inflation rebates and a redesign of Medicare Part D plans, will affect payers and manufacturers.

Gene therapies could have a major impact, although the cost and complexities could inhibit their wide rollout, study authors said.

A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.

A Danish study of nationwide registries estimated a 39% greater risk of high refractive error among children of mothers with hypertensive disorder of pregnancy (HDP), a complication that affects 5% to 10% of pregnancies.

A positive association between asthma and overall cancer risk was found, according to this new study.

However, the patients also said they worried about insufficient care coordination between specialists and other care providers.

This subanalysis of data from the VIRGO study encompassed 2979 patients who had an acute myocardial infarction (AMI), or heart attack, between ages 18 and 55 years; outcomes evaluated included all-cause and cause-specific acute events requiring hospitalization in the year after discharge for a heart attack.

Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.

Patients in this study, who had overall significantly higher scores than controls, fell into 3 categories of psychological risk from temporal lobe epilepsy (TLE) based on analysis with unsupervised machine learning.

A settled class-action lawsuit paves the way for 5 million New Yorkers on Medicaid to have expanded dental coverage; 2 hospitals broke federal law by denying a woman whose life was in danger an abortion; mask mandates in most health care settings are being lifted around the United States.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.

Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.

A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan, discusses how the Braidwood ruling can affect the efficacy of preventive care.

In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).

It is likely that social determinants of health (SDOH) may affect the differences in outcomes from multiple sclerosis (MS) that we see among Black/African American and Hispanic/Latinx populations, absent more data on their genetics and ancestry, noted Mitzi Joi Williams, MD, FAAN.

Challenges around data are mostly around data itself, particularly if it is not timely, says Lee A. Norman, MD, MHS, MBA, the senior medical director for Optum Care Kansas City.

Financial toxicity is defined as financial hardship related to cancer and can have major effects on patients’ quality of life

Survey findings indicate the program was an essential service during the pandemic.

Results from 2 late-stage trials evaluating generalized myasthenia gravis therapies indicated both drugs, rozanolixizumab and zilucoplan, have potential as targeted treatment options.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

Craig D. Pederson, principal at Insight Health Care Partners, discussed the evolving landscape of value-based care and challenges to implementation from the provider perspective during his keynote presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

The study findings suggest that treatments for allergic reactions could help decrease the risk of having joint problems.